Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Next Science Ltd ( (AU:NXS) ) is now available.
Next Science Limited has completed the sale of most of its assets to OSARTIS GmbH for $50 million, with plans to distribute approximately $30 million in net proceeds to shareholders after settling debts and costs. The company has also established transitional agreements to ensure a smooth separation and will seek shareholder approval for the distribution method in a meeting expected to be announced in November 2025.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology, which effectively targets biofilm-based infections in human health. The technology is non-toxic and has proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science fully owns the patent-protected intellectual property related to XBIO™.
YTD Price Performance: 27.83%
Average Trading Volume: 551,038
Technical Sentiment Signal: Sell
Current Market Cap: A$43.16M
For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.